Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vibeke Strand

Showing results (11-20 of 435) with videos related to

Pageof 44
Sort By:
Expert Review of Clinical Immunology|March 3, 2022
Patient-reported outcomes and realistic clinical endpoints for JAK inhibitors in rheumatoid arthritisVibeke Strand
Rheumatology and Therapy|June 11, 2025
Summary of Research: Immunogenicity of Adalimumab Reference Product and Adalimumab-adbm in Patients with Rheumatoid Arthritis, Crohn's Disease, and Chronic Plaque Psoriasis: A Pooled Analysis of the VOLTAIRE trialsVibeke Strand
Current Rheumatology Reports|January 8, 2008
A novel means to demonstrate early efficacy of a product in systemic lupus erythematosusVibeke Strand
Seminars in Arthritis and Rheumatism|February 8, 2006
Measuring quality in arthritis care: the Arthritis Foundation's quality indicator set for rheumatoid arthritisVibeke Strand
Arthritis and Rheumatism|November 13, 2002
Predictors and outcomes of scleroderma renal crisis: data from the high-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trialVibeke Strand
Clinical and Experimental Rheumatology|May 2, 2012
Endpoints for randomised controlled trials in systemic lupus erythematosusMartin Aringer, Vibeke Strand
Clinical Rheumatology|January 7, 2021
Interferon-directed therapies for the treatment of systemic lupus erythematosus: a critical updateYashaar Chaichian, Vibeke Strand
Bulletin of the NYU Hospital for Joint Diseases|October 26, 2010
Rheumatoid arthritis classification criteria - It's finally time to move on!Jeremy Sokolove, Vibeke Strand
Annals of the Academy of Medicine, Singapore|March 17, 2007
Health-related quality of life in patients with systemic lupus erythematosus: an updateJulian Thumboo, Vibeke Strand
Bulletin of the NYU Hospital for Joint Diseases|October 10, 2007
Interleukin-6 inhibition--tolerability profile and clinical implicationsVibeke Strand, Yusuf Yazici
Pageof 44

Showing results (11-20 of 435) with videos related to

Sort By:
Pageof 44
Expert Review of Clinical Immunology|March 3, 2022
Patient-reported outcomes and realistic clinical endpoints for JAK inhibitors in rheumatoid arthritisVibeke Strand
Rheumatology and Therapy|June 11, 2025
Summary of Research: Immunogenicity of Adalimumab Reference Product and Adalimumab-adbm in Patients with Rheumatoid Arthritis, Crohn's Disease, and Chronic Plaque Psoriasis: A Pooled Analysis of the VOLTAIRE trialsVibeke Strand
Current Rheumatology Reports|January 8, 2008
A novel means to demonstrate early efficacy of a product in systemic lupus erythematosusVibeke Strand
Seminars in Arthritis and Rheumatism|February 8, 2006
Measuring quality in arthritis care: the Arthritis Foundation's quality indicator set for rheumatoid arthritisVibeke Strand
Arthritis and Rheumatism|November 13, 2002
Predictors and outcomes of scleroderma renal crisis: data from the high-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trialVibeke Strand
Clinical and Experimental Rheumatology|May 2, 2012
Endpoints for randomised controlled trials in systemic lupus erythematosusMartin Aringer, Vibeke Strand
Clinical Rheumatology|January 7, 2021
Interferon-directed therapies for the treatment of systemic lupus erythematosus: a critical updateYashaar Chaichian, Vibeke Strand
Bulletin of the NYU Hospital for Joint Diseases|October 26, 2010
Rheumatoid arthritis classification criteria - It's finally time to move on!Jeremy Sokolove, Vibeke Strand
Annals of the Academy of Medicine, Singapore|March 17, 2007
Health-related quality of life in patients with systemic lupus erythematosus: an updateJulian Thumboo, Vibeke Strand
Bulletin of the NYU Hospital for Joint Diseases|October 10, 2007
Interleukin-6 inhibition--tolerability profile and clinical implicationsVibeke Strand, Yusuf Yazici
Pageof 44